***Review Article***

**“Integrated Approaches to Diabetes-Induced Vascular and Neurological Complications: Advances, Challenges, and Future Perspectives.”**

**Abstract**

Diabetes mellitus is a major global health burden, with prevalence predicted to spiral exponentially over the next few decades. The chronic metabolic syndrome that this and similar conditions represent is associated with a plethora of vascular and nerve complications that account for substantial morbidity, mortality, and healthcare expenditures. Hyperglycemia-mediated endothelial dysfunction, through its vascular sequelae—microvascular and macrovascular complications—defines angiopathy (e.g., retinopathy, nephropathy) and hypertension (as an example of peripheral arteriolosclerosis), which are pathways for vascular complications. Likewise, neurological complications, including peripheral neuropathy and the comorbid cognitive reserve and information on autonomic dysfunction, are thought to integrate through mechanisms such as axonal transport dysfunction, demyelination, neuronal apoptosis, or Schwann cell dysfunction. Predisposing factors for the coexistence of both complications are overlapping and stem from common pathophysiological pathways, like chronic hyperglycemia and advanced glycation end products (AGEs), emphasizing the need for synergistic therapeutic strategies. New and improved diagnostic techniques, including non-invasive vascular imaging, neuroimaging biomarkers, as well as functional vascular and neurological assessments, have improved early detection. Concurrently, new therapeutic advances such as gene therapy, stem cell-based therapies, RNA therapeutic technologies, and nanomedicine will change the game in the management of diabetic complications. A comprehensive review of diabetes-induced vascular and neuropathological complications based on epidemiology, pathophysiology, diagnostic approaches, and treatment will be presented in the following tutorial review. It is further an overview from a translational perspective and calls for the global implementation of personalized medicine efforts to reduce the global diabetes burden.

**Keywords:** Diabetes complications; Vascular dysfunction; Neurological damage; Hyperglycemia pathways; Diabetic neuropathy; Personalized medicine; Therapeutic innovations

**1. Introduction**

Diabetes mellitus is a common metabolic disorder that has assumed the proportions of a global health emergency, with the accelerated progression of prevalence and life-threatening complications associated with this disease. The International Diabetes Federation (IDF) diabetes atlas 9th edition reported approximately 463 million cases in 2019, with an estimated rise to 578 million by 2030 and 700 million by 2045 globally among adults aged 20–79 years, where an estimated nine percent of the population is living with diabetes. The emerging pandemic is fueled by aging, urbanization, and lifestyle factors, primarily occurring in low- and middle-income countries, as most cases are located here. Type 2 diabetes (T2D) comprises over 90% of all cases, while Type 1 diabetes (T1D) and gestational diabetes mellitus (GDM) are additional pathologies mentioned above (Saeedi et al., 2019). Diabetes complications are the major source of morbidity and mortality globally. Like diabetic vascular complications, cardiovascular disease, retinopathy, and nephropathy are major contributors to poor quality of life and high healthcare costs through neurological complications (e.g., neuropathy, cognitive decline) as well. Current evidence shows the worrying global burden of these complications, which are increasing alongside the incidence of diabetes itself. The overall impact of these complications is much more heavily skewed in favor of low-resource settings, with limited access to early diagnosis and treatment (Harding et al., 2019).

Given the intricate crosstalk between diabetes, vascular, and neurological complications, there is an increasing scope for adopting an integrative understanding of these conditions for their management. Vascular dysfunction and neural damage are intertwined, each with common pathophysiological mechanisms such as chronic hyperglycemia, oxidative stress, and inflammation contributing to the development and progression of one another. A more systemic policy, rather than a single-issue policy, may improve the outcomes and burden of diabetes relative to any associated complications (Y. Li et al., 2023).

This review aims to offer a global overview of the epidemiology of diabetes and its complications, touching upon worldwide trends. Vascular and neurological complications are part and parcel of the whole, hence the importance of an integrated approach for prevention and management. In synthesizing available evidence, the review aims to contribute strategies to reduce the rising burden of diabetes and its complications on global health.

**2. Pathophysiological Mechanisms**

**2.1. Hyperglycemia-Induced Biochemical Pathways**

The pathogenesis of diabetes complications is intricate and multifaceted, with chronic hyperglycemia acting as the main etiological driving force for biochemical and molecular disturbances. Prolonged hyperglycemia causes the activation of interrelated biochemical cascades, leading to endothelial and nerve damage, which eventually precipitates diabetic complications. This section discusses the key hyperglycemia-related pathways involved in the pathogenesis of these complications.

**2.1.1 Polyol Pathway Activation**

In diabetes, the polyol pathway is an essential mode of glucose-induced endothelial dysfunction. Under hyperglycaemic conditions, excessive glucose is diverted into this pathway, where aldose reductase converts glucose to sorbitol, which is then metabolized to fructose through oxidation. As this process depletes NADPH, a cofactor needed for glutathione synthesis, it decreases the cell's antioxidant capability. The accumulation of sorbitol and fructose exerts osmotic stress on macromolecules, leading to oxidative damage, which can result in microvascular complications like diabetic retinopathy or neuropathy (Liu et al., 2012).

**2.1.2 Advanced Glycation End-Products (AGEs) Formation**

Hyperglycemia leads to the non-enzymatic glycation of proteins and lipids, resulting in the formation of advanced glycation end products (AGEs) in a chronic manner. Under this condition, tissues accumulate AGEs that become engaged with their receptor (RAGE), leading to oxidative stress, inflammation, and vascular dysfunction. This process is associated with the pathogenesis of diabetic nephropathy, retinopathy, and cardiovascular disease. Excessive amounts of AGEs also disturb extracellular matrix remodeling and promote fibrosis, worsening organ damage (Singh et al., 2014).

**2.1.3 Protein Kinase C (PKC) Activation**

Inhibition of protein kinase C (PKC) type, especially beta and delta isoforms, under hyperglycemia, is essential to intervene in the pathogenesis of diabetic complications. PKC activation causes endothelial dysfunction by enhancing vascular permeability and nitric oxide bioavailability, reducing inflammation and angiogenesis. Together, these effects lead to microvascular issues (retinopathy/nephropathy) and favor macrovascular atherosclerosis (Pan et al., 2022).

**2.1.4 Hexosamine Pathway Flux**

Extending to excess, glucose is resorbed into the hexosamine biosynthetic pathway, where it is converted to UDP-N-acetylglucosamine (UDP-GlcNAc). This lipid metabolite glycosylates proteins at O-glycosylation sites, interfering with function and increasing insulin resistance, inflammation, and fibrosis. The hexosamine pathway gets activated further in diabetic nephropathy, leading to greater glomerular and tubular injury, which accelerates disease development (Mizukami et al., 2020).

**2.1.5 Oxidative Stress and Inflammation**

The pathogenesis of diabetic complications could be linked by unifying mechanisms: oxidative stress and inflammation. Hyperglycemia triggers a wide range of mitochondrial reactive oxygen species (ROS), leads to the activation of proinflammatory signaling, and causes damage to mitochondrial DNA, proteins, and lipids. Low-grade, chronic inflammation propelled by ROS and hyperglycemia further promotes endothelial dysfunction and tissue damage in many organ systems (Caturano et al., 2024).

**2.2. Vascular Dysfunction**

Vascular dysfunction is an important trait of diabetes and underlies the pathogenesis of micro- and macrovascular complications. Dysfunction is defined as structural and functional alterations throughout the vascular system, mainly related to endothelial cells, the basement membrane, pericytes, and vascular function. In this section, the critical mechanisms involved in vascular dysfunction in diabetes will be reviewed.

**2.2.1 Endothelial Cell Dysfunction**

Early vascular dysfunction in diabetes is best represented by endothelial dysfunction. It is characterized by nitric oxide (NO) insufficiency, augmented oxidative stress, and a proinflammatory condition. Hyperglycemia causes oxidative stress and the generation of reactive oxygen species (ROS), contributing to the uncoupling of endothelial nitric oxide synthase (eNOS) and reducing NO production, leading to decreased vasodilation. This abnormality alone contributes to atherogenesis and increases microvascular complications such as retinopathy and nephropathy. Endothelial dysfunction is a therapeutic target for therapy; for instance, antioxidants or NO donors can be used to counteract these effects (D.-R. Yang et al., 2024).

**2.2.2 Basement Membrane Thickening**

Chronic hyperglycemia in diabetes results in basement membrane thickening, one of the main structural components of blood vessels. This thickening is mainly associated with increased extracellular matrix protein deposition, primarily collagen and laminin, which impair normal vascular behavior. The basement membrane becomes thickened, leading to a decrease in nutrient and oxygen exchange, resulting in microvascular dysfunction with the associated development and proliferation of diabetic complications, notably in the kidney and retina. These data suggest that the mechanisms for basement membrane thickening may identify potential targets for therapeutic interventions to reduce microvascular complications (Salvatore et al., 2022).

**2.2.3 Pericyte Loss**

Pericytes are contractile cells of the capillaries and are essential for the upkeep of vascular stability, regulating blood flow. Loss of pericytes in diabetes is a critical pathological change contributing to diabetic retinopathy. Destruction of pericytes causes vascular leakage, capillary rarefaction, and in later stages leads to retinal ischemia. The reason behind this action is hyperglycemia-induced oxidative damage and inflammation. Existing therapeutic strategies that preserve pericyte function or induce their regeneration might represent promising concepts for the prevention and/or treatment of diabetic retinopathy (C. Li et al., 2024).

**2.2.4 Impaired Vasodilation and Vasoconstriction**

Diabetes impairs vascular reactivity, defined as a decreased capacity of the blood vessels to dilate and constrict properly, which is linked to endothelial dysfunction along with impaired smooth muscle function and changes in the signaling pathways that regulate vascular tone. It results from endothelial dysfunction, altered smooth muscle cell function, and changes in the signaling cascade related to vascular tone, which cannot appropriately respond to a normal stimulus, leading to hypertension and peripheral artery disease. Therapeutic targets aimed at improving vascular reactivity represent a potential strategy that may enhance clinical outcomes in diabetic patients (Jia et al., 2024).

**2.2.5 Angiogenesis Dysregulation**

Abnormal angiogenesis, the sprouting of new capillaries from pre-existing vascular structures, is a hallmark of diabetes due to the disharmony between proangiogenic and antiangiogenic factors. Normally, hypoxia should promote angiogenesis, but the ongoing hyperglycemic milieu leads to inappropriate regulation of key gene expression and failure in vascular remodeling and capillary loss. This dysregulation results in microvascular complications, particularly in the retina and kidneys. Therapeutic strategies targeting angiogenic pathways might offer an alternative avenue to promote vascular health and reduce the inflammatory burden in diabetic patients (Warren, 2019).

**2.3. Neuronal Damage**

Neuronal injury is a major problem associated with diabetes, leading to diabetic neuropathy, the most frequent complication of diabetes, which causes pain, sensory loss, and/or motor dysfunction. In this section, we will describe the principal mechanisms behind neuronal injury in the context of diabetes: demyelination, axonal transport dysfunctions, neuronal apoptosis, neurotrophic factor deficiency, and Schwann cell dysfunctions.

**2.3.1 Axonal Transport Defects**

Peripheral nerve axonal transport defects are of paramount importance for the maintenance and function of neurons, and these are pathophysiological in diabetes induced by the silver lance. The defects, mainly driven by hyperglycemia-mediated oxidative stress and AGE accumulation, cause significant issues. The inability to facilitate axonal transport leads to the disintegration of the axonal delivery of necessary proteins and organelles along the axon, contributing to neuronal malfunction and death. Restoring axonal transport may have a therapeutic effect on diabetic neuropathy (C. Yang et al., 2023).

**2.3.2 Demyelination Processes**

Demyelination is one of the most important pathological changes in diabetic neuropathy that impedes nerve conduction and neuronal function. The demyelination process in diabetes results from metabolic changes, oxidative stress, and inflammatory processes. The lack of myelin sheaths may lead to decreased integrity of nerve fibers and resultant neuropathic pain, as well as sensory loss. Investigating the therapeutic potential of promoting remyelination could open exciting opportunities for treating diabetic neuropathy (Souayah et al., 2024).

**2.3.3 Neuronal Apoptosis**

Neuronal apoptosis, or programmed cell death, is one of the important mechanisms leading to neuronal damage seen in diabetes. Hyperglycemia activates several signaling pathways that culminate in the induction of apoptotic cascades, causing the death of sensory and motor neurons. Key mediators of neuronal apoptosis include oxidative stress, inflammation, and mitochondrial dysfunction. Appreciating these mechanisms could help in developing therapeutic strategies with the ultimate goal of preserving neurons and nerve function from diabetic damage (Yan et al., 2019).

**2.3.4 Schwann Cell Dysfunction**

Schwann cells are necessary for the preservation and repair of peripheral nerves, and disruptions in their function are characteristic of diabetic neuropathy. Oxidative stress and inflammatory cytokines in diabetes have a direct impact on Schwann cell function, leading to damage in myelination and nerve regeneration. This dysfunction worsens neuronal injury and ultimately contributes to diabetic neuropathy. Reversing oxidative stress and inflammation may provide therapeutic measures for Schwann cell repair in order to promote nerve regeneration (J. Li et al., 2023).

**2.3.5 Neurotrophic Factor Deficiency**

Neurotrophic factors are very important for neuronal survival, growth, and regeneration. Neurotrophic factors, such as Nerve Growth Factor (NGF) and Brain-Derived Neurotrophic Factor (BDNF), are neuroprotective, and their deficiency under diabetic neuropathy often leads to neuronal death. This is thought to result in increased neuronal degeneration and a reduced capacity for regeneration in the periphery. Therapeutic strategies focused on neurotrophic factor therapy aim to rescue neuronal survival and promote recovery in the setting of diabetic neuropathy (Galiero et al., 2023).

**3. Vascular Complications**

Vascular problems due to diabetes are severe and associated with substantial morbidity or even mortality. These complications are categorized into two types: macrovascular and microvascular. The remainder of this section is devoted to macrovascular complications, which result from large blood vessel disease and are the major cause of cardiovascular morbidity.

**3.1 Macrovascular Complications**

Macrovascular complications of diabetes mainly include atherosclerosis, cardiovascular complications, cerebrovascular disease, and peripheral arterial disease. All of these complications differ in fundamental pathophysiological mechanisms and related implications.

**3.1.1 Atherosclerosis and Cardiovascular Disease**

* Diabetes is a strong risk factor for atherosclerosis, where plaques develop in the arterial wall, leading to coronary artery disease (CAD) or cardiovascular disease (CVD). The pathophysiology involves multiple interrelated mechanisms associated with one another:
* Chronic Hyperglycemia: Chronic hyperglycemia leads to endothelial dysfunction, which stimulates inflammation and atherogenesis.
* Oxidative stress: ROS production is increased, leading to endothelial cell damage that accelerates the process of plaque formation.
* Inflammation: Diabetes predisposes individuals to an inflammatory response at the site, which thickens the plaque and also seems to provide a suitable environment for rupturing.

Diabetes patients have a 2-4 times increased risk of CVDs compared to non-diabetics. Treatment options include therapeutic lifestyle modifications and pharmacotherapy to lower cardiovascular risk through lifestyle changes such as diet and exercise, as well as pharmacological treatments aimed at blood glucose (hyperglycemia), cholesterol, and blood pressure (Poznyak et al., 2020).

**3.1.2 Cerebrovascular Disease**

Cerebrovascular disease (including stroke) is a major complication of diabetes. Epidemiological studies show that diabetic patients have more strokes and worse outcomes than non-diabetics. Important points:

* + Pathophysiological mechanisms: These include endothelial dysfunction, platelet aggregation mechanisms, and inflammatory processes that are the basis for ischemic stroke in patients, similar to atherosclerosis.
	+ Clinical Impact: Proper glycemic, blood pressure, and cholesterol control are important for the prevention of stroke in diabetic patients.

This is very important to prevent similar future problems and improve clinical outcomes in diabetic groups via these mechanisms (R. Chen et al., 2016).

**3.1.3 Peripheral Arterial Disease**

Peripheral arterial disease (PAD) is a narrowing of the peripheral arteries, usually of the legs, secondary to atherosclerosis. Important aspects of PAD in diabetes are:

* + Epidemiology: Diabetes is established as a major causative factor for PAD, with symptoms such as claudication (leg pain with activity), often progressing to critical limb ischemia.
	+ Mechanism: Endothelial dysfunction, defective nitric oxide, and consequently chronic inflammation result in vascular injury.
	+ Outcomes: Early detection and management are the gold standard for preventing complications such as non-healing ulcers and amputations, including lifestyle changes, medications, and surgery when appropriate.

Knowledge of mechanisms and outcomes for PAD in diabetics is fundamental to management from a systematic approach (Thiruvoipati, 2015).

**3.2. Microvascular Complications**

Microvascular complications of diabetes result from damage to small blood vessels and are important causes of morbidity in diabetes. The major microvascular complications consist of diabetic retinopathy, diabetic nephropathy, and diabetic foot syndrome. The mechanisms of each disease are different, and so too are the clinical implications.

**3.2.1 Diabetic Retinopathy**

Retinopathy of diabetes is the most common cause of vision impairment and blindness in diabetics. Main points:

* Pathophysiology: Chronic hyperglycemia causes retinal microvasculopathy, leading to increased vascular permeability, microaneurysm, and retinal ischemia. Further, the accumulation of advanced glycation end-products (AGE) and oxidative stress exacerbates retinal injury.
* Presentation: Blurred vision, floaters, and at advanced stages, vision loss. Diabetic retinopathy develops from the onset of the disease to advanced stages, including non-proliferative and proliferative diabetic retinopathy (PDR), characterized by the growth of fragile new blood vessels.
* Therapeutic Interventions: Management includes strict glycemic control and regular eye examinations, along with active interventions such as laser photocoagulation and/or anti-VEGF (vascular endothelial growth factor) injections to prevent vision loss (Wang & Lo, 2018).

**3.2.2 Diabetic Nephropathy**

Diabetic nephropathy is defined as progressive kidney damage and a leading cause of end-stage renal disease. Key points are as follows:

* Currently: Diabetic nephropathy usually builds over the years and is characterized by proteinuria, hypertension, and reduced renal function. Early detection is an important step for early intervention.
* Pathophysiology: This condition involves a chronic process of glomerular hyperfiltration, inflammation, and fibrosis, with concomitant elevation of short-term hyperglycemia and hypertension. Its progression is mainly related to the renin-angiotensin-aldosterone system (RAAS).
* Therapies: Current management is essentially directed at glycemic control and the use of either ACE inhibitors or angiotensin receptor blockers (ARBs) to limit progression. Future directions include research on novel therapeutics and biomarkers for early detection (Limonte et al., 2022).

**3.2.3 Diabetic Foot Syndrome**

Diabetic foot syndrome: foot-related complications and amputation. The following are the top key considerations:

* Development: The main reason for this syndrome is a combination of neuropathy and ischemia, which have been explained elsewhere and have been very useful for the ascertainment of both major diseases of modern-day America. Poor diabetic nerves are characterized by a lack of sensation, which increases the likelihood that injuries will go unnoticed. In addition, ischemia from peripheral arterial disease further hampers healing.
* Clinical Practice: Preventative measures include proper foot care such as foot inspection and wearing protective shoes, as well as education about hygiene. Any sort of trauma or infection must be dealt with immediately.
* Control of Medical Management: Wound care, antibiotics for infections, and, when needed, surgery for complications that worsen the condition are essential. Proper glycemic control is also necessary to promote healing and avoid further complications (Raja et al., 2023).

**4. Neurological Complications**

Diabetes-related neurological complications are varied and significant enough to influence the quality of life from a patient's perspective. A very common neurological complication is peripheral neuropathy. The following is a review of distal symmetric polyneuropathy, mononeuropathy, and autonomic neuropathy in this section.

**4.1 Peripheral Neuropathy**

Diabetic peripheral neuropathy can present in different forms; the most common ones include distal symmetric polyneuropathy, mononeuropathies, and autonomic neuropathy.

**4.1.1 Distal Symmetric Polyneuropathy**

Symmetric distal neuropathy is the most common type of diabetic peripheral neuropathy. Key aspects:

* Clinical Manifestations: Symmetrical glove-and-stocking sensory loss in the feet and hands, usually presenting with tingling, burning, or numbness. This results in balance impairments and, hence, an increased risk of falls.
* Pathophysiology: It is majorly preceded by pathophysiological damage to the nerve fiber itself, resulting from hyperglycemia due to mechanisms like oxidative stress and inflammation, as well as the development of AGEs.
* Therapeutic Approaches: Compounds aimed at glycemic control and symptom management include medications such as analgesics (most effective for neuropathic pain), anticonvulsants (e.g., gabapentin), and antidepressant algorithms. Changes in lifestyle, such as exercise and proper foot care, are also important (Smith et al., 2022).

**4.1.2 Mononeuropathies**

Mononeuropathies result from damage to a single nerve or a cluster of nerves that occurs in many locations. Key points:

* Clinical Features: There is an onset of pain, weakness, or loss of sensation that is localized, e.g., in the wrist (carpal tunnel syndrome) or foot.
* Pathophysiology: These neuropathies are usually secondary to the specific nerve being compressed locally due to metabolic changes seen in patients with type 1 and type 2 diabetes.
* Treatment: Treatment is usually targeted at the cause, for example, optimizing blood glucose levels and decompressing the affected nerve. Sometimes, physical therapy and/or surgery is necessary (Bell, 2022).

**4.1.3 Autonomic Neuropathy**

Autonomic neuropathy is a condition that involves a malfunctioning of the autonomic nervous system, which controls the involuntary functions of the body. Some of the important factors to consider are:

* Epidemiology: Autonomic neuropathy frequently occurs in patients with established diabetes and may be syndromic, affecting multiple systems such as cardiovascular, gastrointestinal, or genitourinary.
* Pathophysiology: As in all diabetics, it is neuropathy caused by decades of chronic hyperglycemia, leading to nerve damage and impaired autonomic function.
* Treatment: Generally, management focuses on alleviating symptoms and avoiding complications. For example, medications may be prescribed for orthostatic hypotension, gastroparesis, or bladder dysfunction. Lifestyle modification and regular monitoring are also equally crucial (Williams et al., 2022).

**4.2. Central Nervous System Effects**

CNS — Diabetes has catastrophic effects on the central nervous system (CNS), resulting in cognitive dysfunction, structural brain abnormalities, and a higher incidence of neurodegenerative diseases. This section discusses these imperative elements.

**4.2.1 Cognitive Dysfunction**

Cognitive dysfunction is now increasingly recognized as a major complication of diabetes and diminishes both the quality of life of the patient and their autonomy.

* Mechanisms: The etiological factors associated with cognitive dysfunction in diabetes include hyperglycemia with chronicity, insulin resistance, and oxidative and nitrosative stress. These are known to cause neurovascular injury and deregulate neurotransmitter systems, impairing cognitive domains such as memory, attention, and executive function.
* Clinical Implications: Prospective studies have consistently demonstrated a greater risk of mild cognitive impairment and dementia in patients with diabetes than in people without diabetes. Raising awareness of and providing treatment for decelerating cognitive decline are key components for improving outcomes, including lifestyle modifications and cognitive training (Aderinto et al., 2023).

**4.2.2 Structural Brain Changes**

Neuroimaging studies also reveal that diabetes leads to quite a few structural alterations in the brain.

* Effect of Brain Structure: MRI studies have illustrated that diabetes is associated with reduced volume in the brain, particularly in structures that are important for cognition, such as the hippocampus and pre-frontal cortex. Such changes are associated with cognitive decline and a greater likelihood of neurodegenerative diseases.
* Neuroimaging View: Neuroimaging is a very useful modality for examining aspects of brain structure and shows what diabetes does to the CNS. Identifying these changes can aid in the development of interventions focused on countering the deleterious effects of diabetes on brain health (Gupta et al., 2023).

**4.2.3 Risk of Neurodegenerative Disorders**

Alzheimer's disease and Parkinson's disease are among a group of neurodegenerative disorders that have been correlated with diabetes.

* + Pathophysiological Convergences: The path to neurodegenerative diseases is shared via common risk factors like inflammation, oxidative stress, and insulin resistance with diabetes. These factors may contribute to neuronal degeneration and augment cognitive decline.
	+ Clinical Implications: Being aware of the risk of developing neurodegenerative disorders in the diabetic population is quintessential to early detection and strategies for management. This risk can potentially be lowered by lifestyle modifications, glycemic control, and monitoring for cognitive changes (De La Monte, 2017).

**4.3. Neuro-vascular Interface**

The neurovascular interface is central to protecting the optimal health and function of the nervous system. In diabetes, disruption within this interface is the leading cause of dreadful neurological issues. This part elaborates on the issues of neurovascular uncoupling, blood-brain barrier changes, and blood-brain barrier dysfunction.

**4.3.1 Neurovascular Coupling Disruption**

Neurovascular coupling is the relationship between neuronal activity and the regulation of blood supply to the brain.

* Effect of Diabetes: Diabetes blunts neurovascular coupling, which is affected by inappropriate blood flow to active brain regions during cognitive tasks. This deficit coincides with cognitive dysfunction and may aggravate neurodegenerative processes.
* Mechanisms: Chronic hyperglycemia, oxidative/nitrosative stress, and inflammation are well characterized in their effects on endothelial function as well as on neuronal-vascular signaling pathways that serve a regulatory role for blood flow in response to neuronal activity.
* Clinical Relevance: Given that diabetes is recognized to impair neurovascular coupling, insights into the effects of this impairment on cognition may provide directions for developing therapies to improve cognitive performance and prevent decline (Feng & Gao, 2024).

**4.3.2 Blood-Nerve Barrier Dysfunction**

The Blood-Nerve Barrier (BNB) is a protective immunological interface between systemic circulation and approximately seven peripheral nerves.

* Involvement in diabetic peripheral neuropathy: The breakdown of the blood-nerve barrier is associated with the pathogenesis of diabetic peripheral neuropathy (DPN). The dysfunction of this barrier enables harmful substances to breach the nerve tissue, inducing inflammation and nerve injury.
* Pathophysiological Mechanisms: The blood-nerve barrier can be destabilized by hyperglycemia, oxidative stress, and inflammatory cytokines, leading to elevated permeability and, consequently, nerve injury.
* Clinical Implications: Restoring blood-nerve barrier integrity holds therapeutic implications for the prevention and treatment of diabetic peripheral neuropathy (Richner et al., 2019).

**4.3.3 Blood-Brain Barrier Alterations**

The blood-brain barrier (BBB) is important for maintaining the brain's safety from systemic toxic substances while allowing in neuro-privileged nutrients.

* New Diabetes-Driven Damage: Diabetes can result in changes to the blood-brain barrier that may compromise its integrity and allow potentially neurotoxic substances to enter the brain.
* Function: This dysfunction leads to cognitive impairment and an increased risk of neurodegenerative diseases.
* Mechanism: The alterations of the BBB in the diabetic state are implicated in inflammation and oxidative stress, along with the impairment of tight junction proteins that mediate the barrier function.
* Therapeutic approaches: Knowledge of these pathways will be useful in devising therapeutic strategies to protect the brain from diabetic BBB dysfunction. These may involve pharmacological agents combating inflammation and oxidation (Jeong et al., 2022).

**5. Diagnostic Approaches**

Accurate diagnosis of vascular complications in diabetes is a must for early intervention and management. This section aims to discuss vascular evaluation strategies, non-invasive vascular imaging tools, and indicators of vascular dysfunction, as well as functional vascular tests.

**5.1 Vascular Assessment**

**5.1.1 Non-Invasive Vascular Imaging**

Non-invasive vascular imaging has greatly improved and provides important knowledge in the assessment of vascular complications in patients with diabetes.

* Techniques: Ultrasound, magnetic resonance imaging (MRI), and computed tomography (CT) angiography provide non-invasive visualization of blood vessels.
* Clinical Utility: These imaging modalities aid in the recognition of subclinical atherosclerosis and other vascular complications of diabetes, including PDAM. They are an integral part of risk stratification and therapy guidance.
* Emerging Trends: Innovations in imaging technology have improved vascular assessment capability, resulting in earlier detection and monitoring opportunities for diabetic vascular complications (Hansen & Ripa, 2025).

**5.1.2 Biomarkers of Vascular Damage**

Biomarkers are gaining importance, especially in the discovery of early vascular complications of diabetes in patients with this condition.

* Biomarkers in circulation: Biomarkers that may inform vascular health include inflammatory cytokines, endothelial dysfunction markers (e.g., von Willebrand factor), and advanced glycation end products (AGEs).
* Clinically, understanding vascular-specific biomarkers that are altered due to damage will help in early detection, risk assessment, and surveillance for disease progression, prompting immediate interventions to prevent or alleviate the consequences.
* Specific Findings in Research: Studies have confirmed a correlation between certain circulating biomarkers and the extent of vascular manifestations, suggesting their possible clinical use (Ahmed et al., 2025).

**5.1.3 Functional Vascular Tests**

Blood Vessel Function — Functional vascular tests help us understand the actual function of our blood vessels and are beneficial in diabetic patients for vascular risk stratification.

* Endothelial Function: Endothelial function is assessed by endothelium-dependent flow-mediated dilation (FMD) or non-invasive RHI.
* Methodologies: Endothelial function assessments can be done by several methods, including ultrasound and plethysmography. These tests help in the identification of endothelial dysfunction, which is an early phase of vascular complications.
* Implications for Clinical Practice: Endothelial function is necessary to predict cardiovascular risk in the diabetic patient. It serves as an orienting tool for selecting treatment and preventive measures that can improve vascular health (Dubsky et al., 2023).

**5.2. Neurological Assessment**

Diabetic neuropathy and its related cognitive deficits are best diagnosed, monitored, and treated with careful neurological assessment. This material will elaborate on different assessment modalities, which include electrodiagnostic studies, quantitative sensory testing, high-tech neuroimaging, and biomarkers of neuronal injury.

**5.2.1 Electrodiagnostic Studies**

Nerve conduction studies (NCS), and in particular electrodiagnostic studies, are essential for the study of diabetic neuropathy.

* Utility: NCS are used to determine the speed and function of electrical signals in peripheral nerves, which helps in identifying nerve injuries and dysfunction caused by diabetes.
* Systematic Review: Some evidence exists that NCS can effectively discriminate between types of diabetic neuropathy (e.g., distal symmetric polyneuropathy compared to mononeuropathy). They provide objective information that helps direct treatment and decisions regarding disease progression.
* Clinical Relevance: The results of electrodiagnostic studies are useful for clinicians in making diagnoses, assessing the severity of neuropathy, and evaluating therapeutic responsiveness (Haji Naghi Tehrani, 2018).

**5.2.2 Quantitative Sensory Testing**

Quantitative sensory testing (QST) is a measure of sensory nerve function and is extremely helpful in the diagnosis of diabetic neuropathy.

* Applications: QST examines several sensory modalities (temperature, vibration, thermal pain, and cutaneous latency), providing a quantitative measure of sensory nerve function.
* Limitations: QST is useful for the detection of sensory deficits, but there is a lack of standardization and reproducibility. Results are also sensitive to patient anxiety and testing conditions.
* Clinical Translation: Such limitations notwithstanding, QST can assist in the low-threshold diagnosis of neuropathy and also in the follow-up monitoring of disease course and response to treatment (Burgess et al., 2021).

**5.2.3 Advanced Neuroimaging**

Most recent neuroimaging techniques for assessing diabetic neuropathy as well as cognitive decline associated with it.

* Neuroimaging Biomarkers: MRI/PET scans (structural and functional changes in the brain due to diabetic neuropathy and cognitive impairment).
* Research Implications: Previous research indicates that neuroimaging biomarkers can be linked to clinical observations, suggesting a possible pathophysiologic role for diabetic neuropathy and cognitive consequences.
* Practical Relevance: Hence, advanced neuroimaging techniques can improve diagnostic precision and pave the way for specific therapeutic strategies to minimize neurological sequelae (Ehtewish et al., 2022).

**5.2.4 Biomarkers of Neuronal Damage**

New biomarkers for neuronal damage allow for the detection and monitoring of diabetic neuropathy.

* Classification of Biomarkers: Neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and other proteins related to neuronal injury and inflammation are promising biomarkers.
* Identification of Neuronal Damage: These biomarkers can provide information regarding the severity of neuronal injury and improve early diagnosis and disease monitoring.
* Clinical Implications: Integrating biomarkers into clinical practice may change the management of diabetic neuropathy by enabling timely interventions and individualized remediation plans (Yuan & Nixon, 2021).

**6. Therapeutic Interventions**

**6.1. Glycemic Control**

Management of diabetes needs to address different types of interventions with glycemic control as the bulk of treatment. This segment also elaborates on different therapeutic strategies to achieve optimal glycemic control (oral antidiabetics, insulin, and new strategies in play).

**6.1.1 Oral Antidiabetic Agents**

Regimens of oral antidiabetic agents are the first-line treatment for controlling blood glucose in type 2 diabetes.

* Efficacy and Safety: Recent trials have assessed the efficacy and safety of novel antidiabetic drugs (SGLT2 inhibitors/GLP-1 receptor agonists). Not only do these medications prevent hyperglycemia, but they also have vascular protective effects.
* Clinical Implications: These agents, when used, help to lower the risk of cardiovascular events and improve overall patient outcomes. Familiarizing yourself with the class-specific benefits and risks of different medications is important for individualized therapeutic decisions (Stein et al., 2013).

**6.1.2 Insulin Therapy**

Insulin therapy is still fundamental to glycemic care, especially in cases of type 1 diabetes and advanced type 2 diabetes.

* Developments in Formulations: The recent breakthroughs in insulin formulations (i.e., long-acting and rapid-acting insulins) have increased the ease and convenience of insulin dosing. Formulations are designed to facilitate improved glycemic control without the hypoglycemia risk.
* Delivery Methods: New delivery methods, including insulin pens, pumps, and continuous glucose monitors (CGMs), increase patient compliance with diabetes management. They permit more accurate dosing and monitoringof blood glucose levels.
* Clinical Relevance: Improvements in formulations and delivery methods for insulin can lead to better glycemic control and reduce the risk of complications (Ahmad, 2014).

**6.1.3 Emerging Approaches**

Every day, new strategies emerge to achieve better glycemic control in diabetes.

* Technology Upgradation: Positioning of technologies like smart insulin pens and artificial insulin delivery systems is revamping diabetes management. These technologies allow for the monitoring of insulin delivery as well as readouts for glucose levels in real time to make changes accordingly.
* Perspectives for Treatment Management: Novel therapeutic strategies like dual-action agents that target multiple pathways in glucose homeostasis hold promise for improving glycemic control along with reducing the interference of associated complications.
* Conclusions and Future Directions: Future studies in personalized medicine and artificial intelligence may help optimize treatment strategies according to the individual needs required by patient-oriented ADA guidelines (Sugandh et al., 2023).

**6.2. Targeting Vascular Pathways**

The management of diabetes complications demands a focus on the vascular pathways. In this section, we will discuss different treatment options, including antihypertensive therapy, lipid-lowering strategies, antiplatelet agents, and angiogenic strategies.

**6.2.1 Antihypertensive Therapy**

Hypertension must be controlled for the prevention of vascular complications in a diabetic.

* Effect on vascular complications: It has been found that good blood pressure control can lead to a significant reduction in the percentage of cardiovascular events and other vascular complications in the population affected by diabetes.
* Clinical Relevance: Antihypertensives like ACE inhibitors, ARBs, and diuretics not only lower blood pressure but also provide some protection to the kidneys, thus lessening the chances of complications associated with diabetes (Hayfron-Benjamin et al., 2023).

**6.2.2 Lipid-Lowering Interventions**

In diabetic patients, treatment of dyslipidemia is important for athero-cardiovascular risk reduction.

* Role of statins and PCSK9 inhibitors: Statins are widely used to decrease LDL cholesterol levels and remain effective at reducing cardiovascular events in people with diabetes. Lipid-lowering agents from the newer class of PCSK9 inhibitors offer additional benefits for patients with dyslipidemia that are refractory to treatment.
* Clinical implications: Implementing lipid-lowering therapy will help significantly reduce non-fatal complications of atherosclerosis in diabetes, providing further evidence that cardiovascular disease should be managed as an integrated risk factor (Handelsman & Lepor, 2018).

**6.2.3 Antiplatelet Agents**

Antiplatelet therapy is a central approach to preventing thrombotic events in patients with diabetes.

* Balancing efficacy and bleeding risk: Antiplatelet agents (e.g., aspirin, clopidogrel) are instrumental in decreasing the risk of cardiovascular events but also have bleeding side effects. Hence, judgment regarding benefits and risks is required for each patient.
* • Clinical importance: Guidelines recommend antiplatelet therapy in diabetics with CVD and/or those who are at high risk of CV events, stressing its role within a comprehensive vascular risk management plan (Ajjan & Grant, 2011).

**6.2.4 Angiogenic Therapies**

Angiogenic therapies are intended to reestablish perfusion in tissues affected by ischemia due to diabetic vascular disease.

* Current Status: Research into angiogenic therapy has focused on the creation of new blood vessels to increase perfusion in the affected areas. Strategies currently being studied on an experimental level include those based on growth factors and gene therapy.
* Future Directions: Even proof-of-concept clinical studies of angiogenic therapy for diabetic vascular complications are on the horizon, particularly in patients with critical limb ischemia and other peripheral artery diseases (Han et al., 2022).

**6.3. Neuroprotective Strategies**

The prevention and management of diabetic neuropathy require neuroprotective strategies. Antioxidants and anti-inflammatory agents, growth factors/neurotrophins, ion channel modulators, and Schwann cell-directed therapeutics are all covered in this section.

**6.3.1 Antioxidants and Anti-Inflammatory Agents**

Treatments for Diabetic Neuropathy Should Concentrate on Oxidative Stress and Inflammation

* Oxidative Stress: Oxidative stress plays a major role in neuronal damage in diabetic neuropathy. Free radicals are neutralized by antioxidants, which helps reduce cellular injury.
* Inflammatory Mediators: Inflammation is another key process in the pathophysiology of diabetic neuropathy. Anti-inflammatory agents can attenuate the inflammatory response, which may prevent damage to nerve tissues.
* Clinical Implications: A multi-faceted strategy for diabetic neuropathy, such as a combination of antioxidants and anti-inflammatory agents, seems logical, with in vivo evidence of both improved nerve function and pain response (Sandireddy et al., 2014).

**6.3.2 Growth Factors and Neurotrophins**

Growth factors and neurotrophins have therapeutic potential for nerve repair through healthy nerve regeneration.

* Neurotropic Agents: Nerve growth factor (NGF) and Brain-Derived Neurotrophic Factor (BDNF) support the survival of neurons and promote regeneration. They are crucial for maintaining the health of the peripheral nerves.
* Prospective Use: Research has shown that neurotrophic factors offer an emerging therapeutic approach for enhancing nerve repair and sensory function, according to proponents of interventions in diabetic neuropathy (Xiao & Le, 2016).

**6.3.3 Ion Channel Modulators**

One of the emerging therapeutic avenues in managing diabetic neuropathic pain is through the modulation of ion channels.

* Work Mechanism: Ion channels are key entryways involved in pain pathways. Modulation of these hetero-tetrameric channels changes neuronal excitability and decreases pain perception.
* Clinical Relevance: Sodium channel blockers and calcium channel modulators target ion channel modulators that have shown potential in clinical studies of neuropathic pain in diabetic patients (Petroianu et al., 2023).

**6.3.4 Schwann Cell-Targeted Therapies**

The function of Schwann cells in peripheral nerves is vital, and their dysfunction has been associated with diabetic neuropathy.

* Dysfunction in Diabetic Neuropathy: Schwann cells myelinate and support peripheral nerves. In diabetes, these cells can malfunction, causing diminished regenerative capacity and providing a fertile environment for neuropathic pain.
* Therapeutic implications: The Alteration of Schwann cell function through a wide range of therapies could boost nerve repair and consequently alleviate neuropathy symptoms. Studies are being conducted for the development of potential treatments aimed at restoring the function of Schwann cells and improving patient outcomes (Abd Razak et al., 2024).

**6.4. Emerging Therapeutic Approaches**

New therapeutic modalities are transforming how we manage diabetic complications with innovative strategies to tackle vascular and neurological issues. Gene therapy, stem cell-based interventions, RNA therapeutics, and nanomedicine are discussed in this section.

**6.4.1 Gene Therapy**

Diabetic complications can be targeted at the level of genes with gene therapy, which would finally treat the underlying cause of the disease.

* Prospects: Gene therapy is attempting to recreate the normal physiologic responses through the delivery of therapeutic genes specifically in affected tissues, which could lead to overall restoration and healing of vascular and neurological systems.
* Applications: Gene therapy has shown promise in enhancing angiogenesis in diabetic vascular diseases as well as for neuroprotection against diabetes-induced neuropathy, suggesting novel therapeutic avenues (Srinivasan et al., 2021).

**6.4.2 Stem Cell-Based Interventions**

Stem cell therapy is an actively researched field for regenerating damaged tissues and functional delivery in diabetic patients.

* Latest trends: Novel embryonic stem cell technology has been successfully utilized to generate stem cells with the ability to differentiate into insulin-producing cells, as well as vascular and neural cells, which may contribute to healing and regeneration.
* Conclusions: Currently, ongoing studies are examining the efficacy of stem cell therapy for ameliorating diabetic complications, showing promising results on wound healing, nerve regeneration, and vascular regeneration (Ebrahimi et al., 2021).

**6.4.3 RNA-Based Therapeutics**

RNA therapeutics (e.g., RNA interference (RNAi) and microRNA-based therapies) provide an innovative approach for the post-marketing management of diabetic complications.

* Mechanism: This includes therapies that target specific pathways by which diabetes and its complications progress at the level of RNA, modulating gene expression.
* Role in clinical practice: Research has demonstrated that RNA pathways can decrease inflammation, increase insulin sensitivity, and improve vascular health, suggesting the potential for use in diabetic patients (X. Chen et al., 2018).

**6.4.4 Nanomedicine Approaches**

Through nanomedicine, diabetic complications are managed by applying nanotechnology that accelerates therapeutic delivery and action.

* Cutting-edge applications: Nanoparticles are designed to deliver drugs to the precise target tissues and enable a more efficient therapeutic outcome with fewer unwanted side effects. This approach is especially useful in treating vascular and neurological complications.
* Innovative solutions: Nanomedicine could lead to novel diagnostic methods and biosensors for early detection as well as monitoring of diabetic complications, providing better patient care (He et al., 2021).

**7. Translational Challenges and Future Directions**

Multiple challenges exist in translating research insights into usable clinical practices for the treatment of complications from diabetes. In this section, barriers to clinical translation regarding personalized medicine and remaining gaps in clinical investigation will be discussed.

**7.1 Barriers to Clinical Translation**

While therapies for diabetic complications have seen increased developments, multiple hurdles prevent their successful translational application into clinical practice.

* Regulatory Barriers: The multiple layers in regulatory approvals can be a complex maze; therapies must demonstrate robust safety and efficacy through extensive clinical trials.
* Funding and Resource Allocation: A lack of funds in the research and development process holds back the progression from laboratory to clinic of promising therapies.
* Clinical Trial Design: The challenge lies in designing well-powered clinical trials that reasonably take into account the complexity that diabetic patients represent, impeding efforts to demonstrate the effectiveness of new interventions.
* Implementation Challenges: Introducing new therapies into clinical practice, even in the setting of successful trials, is associated with changes to healthcare systems, provider education, and patient literacy (Nickerson & Dutta, 2012).

**7.2 Personalized Medicine Approaches**

A promising strategy in the management of diabetes and its complications is personalized medicine, where therapies are tailored to patient profiles for specific subsets of patients in the management of diabetes.

* Tailored treatments: Genetic, environmental, and lifestyle influences inform personalized medicine, which serves the goal of increasing efficacy while reducing side effects.
* Clinical Implications: Personalized therapy for better patient results, based on tailored treatment according to the unique needs of each individual, is feasible in diabetes management (Klonoff, 2008).

**7.3 Research Priorities and Unmet Needs**

Research gaps are key to improving the management of diabetic vascular and nerve complications.

* Needs gaps: key areas in the literature need to be reviewed regarding the mechanisms underlying diabetes complications, better therapeutics, and improved diagnostics.
* Future directions for research: The wise choice of research to close these gaps can produce groundbreaking answers to care for people with diabetes. To progress research in this area, there needs to be a collaborative will between researchers, clinicians, and industry stakeholders.

**Conclusion**

Diabetes mellitus is increasingly common, and the consequences of this often-associated condition highlight an imperative to better understand the mechanisms leading to this pandemic for the design of effective preventive and therapeutic approaches in the future. The common pathways underlying vascular diseases (atherosclerosis, retinopathy, and nephropathy), as well as neurological outcomes like peripheral neuropathy and cognitive decline, are continuous hyperglycemia and chronic exposure to oxidative stress with associated inflammation. These comorbidities should be treated with an integrated, systemic approach toward vascular and neurological health. The development of new and improved diagnostics has made earlier diagnosis possible using tools such as non-invasive imaging and biomarkers for vascular and neuronal damage, up to advanced neuroimaging thresholds. Translational hurdles, including regulatory issues, funding limitations, and complexities in designing clinical trials, still exist, but overcoming these barriers needs to be done through an alliance between research institutions, healthcare systems, and industry players. Important steps in the quest for new therapeutics will be taken via innovations such as SGLT2 inhibitors and GLP-1 receptor agonists, which not only improve glycemic control but also offer potential for vascular protection simultaneously. Innovative fields of technology, such as gene therapy and nanomedicine, have also been proposed as possible means to address the antecedents of diabetic complications. Moreover, therapeutic strategies concentrating on oxidative stress, inflammation, and Schwann cell dysfunction aimed at neuroprotecting diabetic neuropathy have been suggested. Personalized medicine paradigms are perhaps one of the most profound opportunities to improve care by de-escalating treatment to an individual patient-based profile that includes genetics, environmental, and lifestyle factors. Advances in research will need to focus on the discovery of new therapies that target early pathological changes, with expanded access in low-resource settings where diabetes has a disproportionately severe impact.

In conclusion, an all-in-one approach, combining diagnostics, therapeutic innovations, and personalized medicine with strong translational strategies, must be employed to mitigate the global burden of diabetes-related vascular and neurodegenerative complications. Filling the current knowledge gaps and enabling innovation across disciplines will bring us closer to real improvements in care and quality of life for patients.

**DISCLAIMER (ARTIFICIAL INTELLIGENCE)**

The author (s) hereby declare that NO generative AI technologies such as Large Language Models (ChatGPT, COPILOT, etc.) and text-to-image generators have been used during the writing or editing of this manuscript.

**References**

Abd Razak, N. H., Idris, J., Hassan, N. H., Zaini, F., Muhamad, N., & Daud, M. F. (2024). Unveiling the Role of Schwann Cell Plasticity in the Pathogenesis of Diabetic Peripheral Neuropathy. *International Journal of Molecular Sciences*, *25*(19), 10785. https://doi.org/10.3390/ijms251910785

Aderinto, N., Olatunji, G., Abdulbasit, M., Ashinze, P., Faturoti, O., Ajagbe, A., Ukoaka, B., & Aboderin, G. (2023). The impact of diabetes in cognitive impairment: A review of current evidence and prospects for future investigations. *Medicine*, *102*(43), e35557. https://doi.org/10.1097/MD.0000000000035557

Ahmad, A. (2014). Recent Advances in Insulin Therapy for Diabetes. *International Journal of Diabetes and Clinical Research*, *1*(1). https://doi.org/10.23937/2377-3634/1410006

Ahmed, S., Adnan, H., Khawaja, M. A., & Butler, A. E. (2025). Novel Micro-Ribonucleic Acid Biomarkers for Early Detection of Type 2 Diabetes Mellitus and Associated Complications—A Literature Review. *International Journal of Molecular Sciences*, *26*(2), 753. https://doi.org/10.3390/ijms26020753

Ajjan, R. A., & Grant, P. J. (2011). The Role of Antiplatelets in Hypertension and Diabetes Mellitus. *The Journal of Clinical Hypertension*, *13*(4), 305–313. https://doi.org/10.1111/j.1751-7176.2011.00431.x

Bell, D. S. H. (2022). Diabetic Mononeuropathies and Diabetic Amyotrophy. *Diabetes Therapy*, *13*(10), 1715–1722. https://doi.org/10.1007/s13300-022-01308-x

Burgess, J., Frank, B., Marshall, A., Khalil, R. S., Ponirakis, G., Petropoulos, I. N., Cuthbertson, D. J., Malik, R. A., & Alam, U. (2021). Early Detection of Diabetic Peripheral Neuropathy: A Focus on Small Nerve Fibres. *Diagnostics*, *11*(2), 165. https://doi.org/10.3390/diagnostics11020165

Caturano, A., Nilo, R., Nilo, D., Russo, V., Santonastaso, E., Galiero, R., Rinaldi, L., Monda, M., Sardu, C., Marfella, R., & Sasso, F. C. (2024). Advances in Nanomedicine for Precision Insulin Delivery. *Pharmaceuticals*, *17*(7), 945. https://doi.org/10.3390/ph17070945

Chen, R., Ovbiagele, B., & Feng, W. (2016). Diabetes and Stroke: Epidemiology, Pathophysiology, Pharmaceuticals and Outcomes. *The American Journal of the Medical Sciences*, *351*(4), 380–386. https://doi.org/10.1016/j.amjms.2016.01.011

Chen, X., Mangala, L. S., Rodriguez-Aguayo, C., Kong, X., Lopez-Berestein, G., & Sood, A. K. (2018). RNA interference-based therapy and its delivery systems. *Cancer and Metastasis Reviews*, *37*(1), 107–124. https://doi.org/10.1007/s10555-017-9717-6

De La Monte, S. M. (2017). Insulin Resistance and Neurodegeneration: Progress Towards the Development of New Therapeutics for Alzheimer’s Disease. *Drugs*, *77*(1), 47–65. https://doi.org/10.1007/s40265-016-0674-0

Dubsky, M., Veleba, J., Sojakova, D., Marhefkova, N., Fejfarova, V., & Jude, E. B. (2023). Endothelial Dysfunction in Diabetes Mellitus: New Insights. *International Journal of Molecular Sciences*, *24*(13), 10705. https://doi.org/10.3390/ijms241310705

Ebrahimi, A., Ahmadi, H., Pourfraidon Ghasrodashti, Z., Tanide, N., Shahriarirad, R., Erfani, A., Ranjbar, K., & Ashkani-Esfahani, S. (2021). Therapeutic effects of stem cells in different body systems, a novel method that is yet to gain trust: A comprehensive review. *Bosnian Journal of Basic Medical Sciences*. https://doi.org/10.17305/bjbms.2021.5508

Ehtewish, H., Arredouani, A., & El-Agnaf, O. (2022). Diagnostic, Prognostic, and Mechanistic Biomarkers of Diabetes Mellitus-Associated Cognitive Decline. *International Journal of Molecular Sciences*, *23*(11), 6144. https://doi.org/10.3390/ijms23116144

Feng, L., & Gao, L. (2024). The role of neurovascular coupling dysfunction in cognitive decline of diabetes patients. *Frontiers in Neuroscience*, *18*, 1375908. https://doi.org/10.3389/fnins.2024.1375908

Galiero, R., Caturano, A., Vetrano, E., Beccia, D., Brin, C., Alfano, M., Di Salvo, J., Epifani, R., Piacevole, A., Tagliaferri, G., Rocco, M., Iadicicco, I., Docimo, G., Rinaldi, L., Sardu, C., Salvatore, T., Marfella, R., & Sasso, F. C. (2023). Peripheral Neuropathy in Diabetes Mellitus: Pathogenetic Mechanisms and Diagnostic Options. *International Journal of Molecular Sciences*, *24*(4), 3554. https://doi.org/10.3390/ijms24043554

Gupta, M., Pandey, S., Rumman, M., Singh, B., & Mahdi, A. A. (2023). Molecular mechanisms underlying hyperglycemia associated cognitive decline. *IBRO Neuroscience Reports*, *14*, 57–63. https://doi.org/10.1016/j.ibneur.2022.12.006

Haji Naghi Tehrani, K. (2018). A Study of Nerve Conduction Velocity in Diabetic Patients and its Relationship with Tendon Reflexes (T-Reflex). *Open Access Macedonian Journal of Medical Sciences*, *6*(6), 1072–1076. https://doi.org/10.3889/oamjms.2018.262

Han, J., Luo, L., Marcelina, O., Kasim, V., & Wu, S. (2022). Therapeutic angiogenesis-based strategy for peripheral artery disease. *Theranostics*, *12*(11), 5015–5033. https://doi.org/10.7150/thno.74785

Handelsman, Y., & Lepor, N. E. (2018). PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review. *Journal of the American Heart Association*, *7*(13), e008953. https://doi.org/10.1161/JAHA.118.008953

Hansen, T. W., & Ripa, R. S. (2025). Advances in Imaging Techniques for Assessing Myocardial Microcirculation in People with Diabetes: An Overview of Current Techniques, Emerging Techniques, and Clinical Applications. *Diabetes Therapy*. https://doi.org/10.1007/s13300-025-01710-1

Harding, J. L., Pavkov, M. E., Magliano, D. J., Shaw, J. E., & Gregg, E. W. (2019). Global trends in diabetes complications: A review of current evidence. *Diabetologia*, *62*(1), 3–16. https://doi.org/10.1007/s00125-018-4711-2

Hayfron-Benjamin, C. F., Quartey-Papafio, T. R., Amo-Nyarko, T., Antwi, E. A., Vormatu, P., Agyei-Fedieley, M. K., & Obeng, K. A. (2023). Relationships of blood pressure and control with microvascular dysfunction in type 2 diabetes. *Diabetes Epidemiology and Management*, *12*, 100160. https://doi.org/10.1016/j.deman.2023.100160

He, Y., Al-Mureish, A., & Wu, N. (2021). Nanotechnology in the Treatment of Diabetic Complications: A Comprehensive Narrative Review. *Journal of Diabetes Research*, *2021*, 1–11. https://doi.org/10.1155/2021/6612063

Jeong, J., Lee, D. H., & Song, J. (2022). HMGB1 signaling pathway in diabetes-related dementia: Blood-brain barrier breakdown, brain insulin resistance, and Aβ accumulation. *Biomedicine & Pharmacotherapy*, *150*, 112933. https://doi.org/10.1016/j.biopha.2022.112933

Jia, G., Bai, H., Mather, B., Hill, M. A., Jia, G., & Sowers, J. R. (2024). Diabetic Vasculopathy: Molecular Mechanisms and Clinical Insights. *International Journal of Molecular Sciences*, *25*(2), 804. https://doi.org/10.3390/ijms25020804

Klonoff, D. C. (2008). Personalized Medicine for Diabetes. *Journal of Diabetes Science and Technology*, *2*(3), 335–341. https://doi.org/10.1177/193229680800200301

Li, C., Chen, X., Zhang, S., Liang, C., Deng, Q., Li, X., & Yan, H. (2024). Pericyte loss via glutaredoxin2 downregulation aggravates diabetes-induced microvascular dysfunction. *Experimental Eye Research*, *247*, 110025. https://doi.org/10.1016/j.exer.2024.110025

Li, J., Guan, R., & Pan, L. (2023). Mechanism of Schwann cells in diabetic peripheral neuropathy: A review. *Medicine*, *102*(1), e32653. https://doi.org/10.1097/MD.0000000000032653

Li, Y., Liu, Y., Liu, S., Gao, M., Wang, W., Chen, K., Huang, L., & Liu, Y. (2023). Diabetic vascular diseases: Molecular mechanisms and therapeutic strategies. *Signal Transduction and Targeted Therapy*, *8*(1), 152. https://doi.org/10.1038/s41392-023-01400-z

Limonte, C. P., Kretzler, M., Pennathur, S., Pop-Busui, R., & De Boer, I. H. (2022). Present and future directions in diabetic kidney disease. *Journal of Diabetes and Its Complications*, *36*(12), 108357. https://doi.org/10.1016/j.jdiacomp.2022.108357

Liu, J.-W., Liu, D., Cui, K.-Z., Xu, Y., Li, Y.-B., Sun, Y.-M., & Su, Y. (2012). Recent advances in understanding the biochemical and molecular mechanism of diabetic cardiomyopathy. *Biochemical and Biophysical Research Communications*, *427*(3), 441–443. https://doi.org/10.1016/j.bbrc.2012.09.058

Mizukami, H., Osonoi, S., Takaku, S., Yamagishi, S.-I., Ogasawara, S., Sango, K., Chung, S., & Yagihashi, S. (2020). Role of glucosamine in development of diabetic neuropathy independent of the aldose reductase pathway. *Brain Communications*, *2*(2), fcaa168. https://doi.org/10.1093/braincomms/fcaa168

Nickerson, H. D., & Dutta, S. (2012). Diabetic Complications: Current Challenges and Opportunities. *Journal of Cardiovascular Translational Research*, *5*(4), 375–379. https://doi.org/10.1007/s12265-012-9388-1

Pan, D., Xu, L., & Guo, M. (2022). The role of protein kinase C in diabetic microvascular complications. *Frontiers in Endocrinology*, *13*, 973058. https://doi.org/10.3389/fendo.2022.973058

Petroianu, G. A., Aloum, L., & Adem, A. (2023). Neuropathic pain: Mechanisms and therapeutic strategies. *Frontiers in Cell and Developmental Biology*, *11*, 1072629. https://doi.org/10.3389/fcell.2023.1072629

Poznyak, A., Grechko, A. V., Poggio, P., Myasoedova, V. A., Alfieri, V., & Orekhov, A. N. (2020). The Diabetes Mellitus–Atherosclerosis Connection: The Role of Lipid and Glucose Metabolism and Chronic Inflammation. *International Journal of Molecular Sciences*, *21*(5), 1835. https://doi.org/10.3390/ijms21051835

Raja, J. M., Maturana, M. A., Kayali, S., Khouzam, A., & Efeovbokhan, N. (2023). Diabetic foot ulcer: A comprehensive review of pathophysiology and management modalities. *World Journal of Clinical Cases*, *11*(8), 1684–1693. https://doi.org/10.12998/wjcc.v11.i8.1684

Richner, M., Ferreira, N., Dudele, A., Jensen, T. S., Vaegter, C. B., & Gonçalves, N. P. (2019). Functional and Structural Changes of the Blood-Nerve-Barrier in Diabetic Neuropathy. *Frontiers in Neuroscience*, *12*, 1038. https://doi.org/10.3389/fnins.2018.01038

Saeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., Colagiuri, S., Guariguata, L., Motala, A. A., Ogurtsova, K., Shaw, J. E., Bright, D., & Williams, R. (2019). Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. *Diabetes Research and Clinical Practice*, *157*, 107843. https://doi.org/10.1016/j.diabres.2019.107843

Salvatore, T., Galiero, R., Caturano, A., Vetrano, E., Loffredo, G., Rinaldi, L., Catalini, C., Gjeloshi, K., Albanese, G., Di Martino, A., Docimo, G., Sardu, C., Marfella, R., & Sasso, F. C. (2022). Coronary Microvascular Dysfunction in Diabetes Mellitus: Pathogenetic Mechanisms and Potential Therapeutic Options. *Biomedicines*, *10*(9), 2274. https://doi.org/10.3390/biomedicines10092274

Sandireddy, R., Yerra, V. G., Areti, A., Komirishetty, P., & Kumar, A. (2014). Neuroinflammation and Oxidative Stress in Diabetic Neuropathy: Futuristic Strategies Based on These Targets. *International Journal of Endocrinology*, *2014*, 1–10. https://doi.org/10.1155/2014/674987

Singh, V. P., Bali, A., Singh, N., & Jaggi, A. S. (2014). Advanced Glycation End Products and Diabetic Complications. *The Korean Journal of Physiology & Pharmacology*, *18*(1), 1. https://doi.org/10.4196/kjpp.2014.18.1.1

Smith, S., Normahani, P., Lane, T., Hohenschurz-Schmidt, D., Oliver, N., & Davies, A. H. (2022). Pathogenesis of Distal Symmetrical Polyneuropathy in Diabetes. *Life*, *12*(7), 1074. https://doi.org/10.3390/life12071074

Souayah, N., Chen, H., Chong, Z. Z., Patel, T., Pahwa, A., Menkes, D. L., & Cunningham, T. (2024). Novel strategy: Identifying new markers for demyelination in diabetic distal symmetrical polyneuropathy. *Heliyon*, *10*(9), e30419. https://doi.org/10.1016/j.heliyon.2024.e30419

Srinivasan, M., Thangaraj, S. R., & Arzoun, H. (2021). Gene Therapy—Can it Cure Type 1 Diabetes? *Cureus*. https://doi.org/10.7759/cureus.20516

Stein, S. A., Lamos, E. M., & Davis, S. N. (2013). A review of the efficacy and safety of oral antidiabetic drugs. *Expert Opinion on Drug Safety*, *12*(2), 153–175. https://doi.org/10.1517/14740338.2013.752813

Sugandh, F., Chandio, M., Raveena, F., Kumar, L., Karishma, F., Khuwaja, S., Memon, U. A., Bai, K., Kashif, M., Varrassi, G., Khatri, M., & Kumar, S. (2023). Advances in the Management of Diabetes Mellitus: A Focus on Personalized Medicine. *Cureus*. https://doi.org/10.7759/cureus.43697

Thiruvoipati, T. (2015). Peripheral artery disease in patients with diabetes: Epidemiology, mechanisms, and outcomes. *World Journal of Diabetes*, *6*(7), 961. https://doi.org/10.4239/wjd.v6.i7.961

Wang, W., & Lo, A. C. Y. (2018). Diabetic Retinopathy: Pathophysiology and Treatments. *International Journal of Molecular Sciences*, *19*(6), 1816. https://doi.org/10.3390/ijms19061816

Warren, A. M. (2019). Diabetic nephropathy: An insight into molecular mechanisms and emerging therapies. *Expert Opinion on Therapeutic Targets*, *23*(7), 579–591. https://doi.org/10.1080/14728222.2019.1624721

Williams, S., Raheim, S. A., Khan, M. I., Rubab, U., Kanagala, P., Zhao, S. S., Marshall, A., Brown, E., & Alam, U. (2022). Cardiac Autonomic Neuropathy in Type 1 and 2 Diabetes: Epidemiology, Pathophysiology, and Management. *Clinical Therapeutics*, *44*(10), 1394–1416. https://doi.org/10.1016/j.clinthera.2022.09.002

Xiao, N., & Le, Q.-T. (2016). Neurotrophic Factors and Their Potential Applications in Tissue Regeneration. *Archivum Immunologiae et Therapiae Experimentalis*, *64*(2), 89–99. https://doi.org/10.1007/s00005-015-0376-4

Yan, W., Pang, M., Yu, Y., Gou, X., Si, P., Zhawatibai, A., Zhang, Y., Zhang, M., Guo, T., Yi, X., & Chen, L. (2019). The neuroprotection of liraglutide on diabetic cognitive deficits is associated with improved hippocampal synapses and inhibited neuronal apoptosis. *Life Sciences*, *231*, 116566. https://doi.org/10.1016/j.lfs.2019.116566

Yang, C., Zhao, X., An, X., Zhang, Y., Sun, W., Zhang, Y., Duan, Y., Kang, X., Sun, Y., Jiang, L., & Lian, F. (2023). Axonal transport deficits in the pathogenesis of diabetic peripheral neuropathy. *Frontiers in Endocrinology*, *14*, 1136796. https://doi.org/10.3389/fendo.2023.1136796

Yang, D.-R., Wang, M.-Y., Zhang, C.-L., & Wang, Y. (2024). Endothelial dysfunction in vascular complications of diabetes: A comprehensive review of mechanisms and implications. *Frontiers in Endocrinology*, *15*, 1359255. https://doi.org/10.3389/fendo.2024.1359255

Yuan, A., & Nixon, R. A. (2021). Neurofilament Proteins as Biomarkers to Monitor Neurological Diseases and the Efficacy of Therapies. *Frontiers in Neuroscience*, *15*, 689938. https://doi.org/10.3389/fnins.2021.689938